Trials / Unknown
UnknownNCT06110676
A Study to Evaluate the Efficacy and Safety of LZM012
A Muti-center, Randomized, Double Blind, Positive Control Phase III Clinical Study to Evaluate the Efficacy and Safety of LZM012 in Moderate to Severe Chronic Plaque Psoriasis Patients
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 918 (estimated)
- Sponsor
- Livzon Pharmaceutical Group Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a muti-center, randomized, double blind, positive control phase III clinical study to evaluate the efficacy and safety of LZM012 in moderate to severe chronic plaque psoriasis patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | LZM012 | Recombinant anti-human IL-17A/F humanized monoclonal antibody injection |
| BIOLOGICAL | Secukinumab | Cosentyx |
Timeline
- Start date
- 2023-08-21
- Primary completion
- 2025-04-01
- Completion
- 2025-06-01
- First posted
- 2023-11-01
- Last updated
- 2023-11-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06110676. Inclusion in this directory is not an endorsement.